| Trial name or title | Efficacy and safety of rituximab to that of calcineurin inhibitors in children with steroid resistant nephrotic syndrome |
| Methods | Open label RCT |
| Participants | Children aged 3 to 16 years with SRNS (MCD, MesPGN or FSGS) |
| Interventions | Rituximab infusions weekly for 2 to 4 doses over up to 4 weeks compared with oral tacrolimus given until the child has achieved 6 months of relapse free survival |
| Outcomes | 12‐month relapse‐free survival in the ITT population; adverse effects |
| Starting date | March 2015; estimated enrolment 120 children |
| Contact information | Dr. Biswanath Basu, Nilratan Sircar Medical College, India (basuv3000@gmail.com) |
| Notes | Estimated study completion date March 2017 Other study numbers: PednephroRCT/PM/NRSMCH‐33, CTRI/2015/01/005364 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.